title: Type 2 diabetes mellitus and Invokana: an FDA approved drug.
abstract: Diabetes Mellitus is a chronic metabolic disease affecting wide range of people across the globe. In India the rate of subjects being suffered from diabetes is continuously increasing. So, the development of drugs for its effective treatment is essential. Thereby, various attempts have been made to discover newer drugs, to reduce the rate of anti diabetic occurrence. Anti-diabetic drugs were found to treat diabetes mellitus by lowering glucose levels in the blood. Both the use antidiabetic drugs as well as the changes in lifestyle and proper diet can significantly affect the severity of diabetes mellitus and also reduces the symptoms and occurrence of the disease. Researches in the past few years on diabetes mellitus showed that this disease is spreading at a very faster rate, thereby; various attempts have been made to treat it efficaciously. Development and approval of antidiabetic drugs is quite necessary. There are different classes of anti-diabetic drugs reported to treat diabetes. The objective of the present review is to explore Invokana as a newly approved antidiabetic drug for the effective treatment of type 2 diabetes. This review focuses mainly on the various aspects of diabetes mellitus and its treatment perspectives. From the various clinical studies done on Invokana, it was concluded that and Invokana was found to be very effective for the efficacious therapy of diabetes mellitus.
authors.affiliation: H. No. 1559, near Old P.O. Pakbara, Moradabad-244001, Uttar Pradesh, India. nidakhtr378@gmail.com.
authors.forename: Nida
authors.initials: N
authors.lastname: Akhtar
mesh_terms: D001786:Blood Glucose / Q000187:drug effects; D000068896:Canagliflozin; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D017277:Drug Approval; D005260:Female; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007194:India / Q000453:epidemiology; D008019:Life Style; D008297:Male; D009765:Obesity / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D013876:Thiophenes / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D001786:Blood Glucose; D005960:Glucosides; D007004:Hypoglycemic Agents; D013876:Thiophenes; D000068896:Canagliflozin